Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 9/20 | 0.58 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429919 | 1.00 | CASR (0.58) | CASRPTPRBUSP30GPR119UCHL1 | |
| SCHEMBL4218285 | 0.91 | CASR (0.59) | CASRPTPRBUSP30GPR119UCHL1 | |
| SCHEMBL4218279 | 0.91 | CASR (0.59) | CASRPTPRBUSP30GPR119UCHL1 | |
| SCHEMBL14189779 | 0.87 | CASR (0.61) | CASRHDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL3676007 | 0.85 | CASR (0.65) | CASRPTPRBUSP30GPR119ENPP2 | |
| SCHEMBL2429936 | 0.85 | CASR (0.61) | CASRHDAC1HDAC2LMNA | |
| SCHEMBL2429940 | 0.85 | CASR (0.61) | CASRHDAC1HDAC2LMNA | |
| SCHEMBL2432965 | 0.84 | CASR (0.64) | CASRHDAC1HDAC2LMNA | |
| SCHEMBL4041031 | 0.83 | CASR (0.65) | CASRPTPRB | |
| SCHEMBL2427869 | 0.81 | CASR (0.72) | CASRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | CASR 2/4885PTPRB 3735/4885USP30 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.